Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
复制标题
DOI：
10.1212/01.wnl.0000137050.43114.42
复制
发表时间：
2004-09-14
期刊：
影响因子：
9.9
通讯作者：
Abrey, LE
中科院分区：
文献类型：
--
作者：
Enting, RH;Demopoulos, A;Abrey, LE
作者评价了利妥昔单抗和替莫唑胺联合治疗复发性或难治性原发性CNS淋巴瘤（PCNSL）的疗效。15例中位年龄为69岁的患者的客观缓解率为53%，毒性可接受。中位总生存期为14个月，缓解患者的中位无进展生存期为7.7个月。这种组合值得进一步研究，并为老年患者进行性PCNSL提供了一个合理的治疗选择。
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.